Abramson Cancer Center at Penn Medicine
This is a single institution single arm feasibility study of MRI-guided, personalized adaptive radiation therapy with reduced margins for patients with glioblastoma.
The goal of this study is to evaluate MRI-guided adaptive radiation therapy to personalize radiotherapy planning for patients with glioblastoma, reduce margins, minimize toxicity, and improve survival.
Inclusion Criteria: * Histologically confirmed IDH-wildtype glioblastoma (WHO Grade 4) * Age ≥ 18 years * Karnofsky Performance Status ≥ 60 * Planned 30 or 15 fractions of radiation therapy with or without concurrent systemic therapy * Ability to undergo MRI imaging with IV gadolinium contrast * Ability to provide written informed consent * Multifocal tumors permitted if clinician anticipates they will be encompassed in a single radiation plan Exclusion Criteria: * Prior intracranial radiotherapy * Multicentric disease * Leptomeningeal dissemination * Pregnancy
The study intervention is MRI-guided adaptive radiation therapy with reduced treatment margins among patients with glioblastoma.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.